PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.51

Change

+0.10 (+2.93)%

Market Cap

N/A

Volume

1.52M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.76 (+0.39%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-1.77 (-0.17%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

-1.54 (-0.57%)

USD 34.86B
ARGX argenx NV ADR

-13.04 (-2.40%)

USD 32.89B
MRNA Moderna Inc

-0.87 (-1.42%)

USD 25.27B
BGNE BeiGene Ltd

+12.40 (+5.31%)

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

+5.86 (+1.67%)

USD 15.95B
SMMT Summit Therapeutics PLC

+0.48 (+2.58%)

USD 15.35B
PCVX Vaxcyte Inc

+0.21 (+0.19%)

USD 14.00B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -60.38% 22% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.38% 22% F 12% F
Trailing 12 Months  
Capital Gain -60.47% 22% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.47% 22% F 13% F
Trailing 5 Years  
Capital Gain -82.65% 37% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.65% 37% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain -20.00% N/A N/A 17% F
Dividend Return -20.00% N/A N/A 17% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.08% N/A N/A 69% C-
Risk Adjusted Return -79.75% N/A N/A 10% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector